statnews.com·May 21, 2026
In this episode of "The Readout LOUD," hosts discuss insights from STAT's Breakthrough Summit West, including comments from BridgeBio CEO Neil Kumar on research publication standards, and feature an interview with Retro Biosciences CEO Joe Betts-LaCroix about the impact of AI on drug development as the company prepares for its first clinical data readout.
Retro Biosciences is preparing for its first clinical data readout, with a focus on exploring the impact of AI in drug development. This signals an opportunity for investors and professionals in AI drug discovery to monitor Retro's progress, as successful integration of AI could enhance drug development efficiency and outcomes.